EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly

EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly

EVA Pharma (https://www.EVAPharma.com) is celebrating the completion of its new biologics’ facility in Cairo, which is set to start producing high-quality insulin next month as part of an ongoing collaboration with Eli Lilly and Company to expand sustainable access to the essential medical product.

In a first for both companies, EVA Pharma and Lilly entered a novel agreement December 2022 in which Lilly supplies its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma, along with a pro-bono technology transfer.

“The completion of this state-of-the-art facility is a critical milestone on the path to provide high-quality, affordable insulin in Egypt and throughout Africa. With a production capacity of 90 million vials and 50 million cartridges, we will eventually reach at least one million people annually in low- to middle-income countries,” said Riad Armanious, EVA Pharma’s CEO.

"We are committed to transforming healthcare in Africa and the Middle East by localizing the manufacturing of life-saving treatments like insulin. With the inauguration of our biologics’ facility, we are proud to be at the forefront of this effort. This is not only vital for the long-term sustainability of healthcare systems but also for empowering local communities and building more resilient healthcare